145 related articles for article (PubMed ID: 33960504)
1. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
Jackson CGCA; Hung T; Segelov E; Barlow P; Prenen H; McLaren B; Hung NA; Clarke K; Chao TY; Dai MS; Yeh HT; Cutler DL; Kramer D; He J; Zhi J; Chan WK; Kwan R; Deva S
Br J Clin Pharmacol; 2021 Dec; 87(12):4670-4680. PubMed ID: 33960504
[TBL] [Abstract][Full Text] [Related]
2. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
Dai MS; Chao TC; Chiu CF; Lu YS; Shiah HS; Jackson CGCA; Hung N; Zhi J; Cutler DL; Kwan R; Kramer D; Chan WK; Qin A; Tseng KC; Hung CT; Chao TY
Ther Adv Med Oncol; 2023; 15():17588359231183680. PubMed ID: 37492633
[TBL] [Abstract][Full Text] [Related]
3. Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
Rugo HS; Umanzor GA; Barrios FJ; Vasallo RH; Chivalan MA; Bejarano S; Ramírez JR; Fein L; Kowalyszyn RD; Kramer ED; Wang H; Kwan MR; Cutler DL;
J Clin Oncol; 2023 Jan; 41(1):65-74. PubMed ID: 35858154
[TBL] [Abstract][Full Text] [Related]
4. Oral docetaxel plus encequidar - a phase 1 clinical trial.
Wang D; Hung N; Hung T; Eden K; Chan WK; Kwan R; Qin A; Chang C; Duffull S; Glue P; Jackson C
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38814342
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Ma WW; Li JJ; Azad NS; Lam ET; Diamond JR; Dy GK; Opyrchal M; Zhi J; Kramer D; Chan WK; Cutler D; Kwan R; Adjei AA; Jimeno A
Cancer Chemother Pharmacol; 2022 Jul; 90(1):7-17. PubMed ID: 35731258
[TBL] [Abstract][Full Text] [Related]
6. Oral delivery of taxanes.
Malingré MM; Beijnen JH; Schellens JH
Invest New Drugs; 2001 May; 19(2):155-62. PubMed ID: 11392449
[TBL] [Abstract][Full Text] [Related]
7. Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.
Sharma D; Wojtynek J; Fox KM; Cooper C; Dokubo I
Am J Manag Care; 2021 Feb; 27(2 Spec. No.):SP46-SP50. PubMed ID: 33395244
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
Smolinski MP; Urgaonkar S; Pitzonka L; Cutler M; Lee G; Suh KH; Lau JYN
J Med Chem; 2021 Apr; 64(7):3677-3693. PubMed ID: 33729781
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.
He J; Jackson CGCA; Deva S; Hung T; Clarke K; Segelov E; Chao TY; Dai MS; Yeh HT; Ma WW; Kramer D; Chan WK; Kwan R; Cutler D; Zhi J
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):867-879. PubMed ID: 35470967
[TBL] [Abstract][Full Text] [Related]
10. HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and
Zeng W; Kwan Law BY; Wai Wong VK; Bik Chan DS; Fai Mok SW; Ying Gao JJ; Yan Ho RK; Liang X; Li JH; Lee MT; Yoon WL; Smolinski MP; Nam Lau JY; Kei Lam CW; Fok M
Cancer Biol Med; 2020 Nov; 17(4):986-1001. PubMed ID: 33299648
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
Hong YS; Kim KP; Lim HS; Bae KS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim H; Kim TW
Invest New Drugs; 2013 Jun; 31(3):616-22. PubMed ID: 22695940
[TBL] [Abstract][Full Text] [Related]
13. Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects.
Abebe BT; Weiss M; Modess C; Roustom T; Tadken T; Wegner D; Schwantes U; Neumeister C; Schulz HU; Scheuch E; Siegmund W
J Clin Pharmacol; 2019 Oct; 59(10):1319-1330. PubMed ID: 30973998
[TBL] [Abstract][Full Text] [Related]
14. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
Yang S; Gursoy RN; Lambert G; Benita S
Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
[TBL] [Abstract][Full Text] [Related]
15. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.
Woo JS; Lee CH; Shim CK; Hwang SJ
Pharm Res; 2003 Jan; 20(1):24-30. PubMed ID: 12608532
[TBL] [Abstract][Full Text] [Related]
16. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats.
Föger F; Malaivijitnond S; Wannaprasert T; Huck C; Bernkop-Schnürch A; Werle M
J Drug Target; 2008 Feb; 16(2):149-55. PubMed ID: 18274935
[TBL] [Abstract][Full Text] [Related]
17. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
Callies S; de Alwis DP; Harris A; Vasey P; Beijnen JH; Schellens JH; Burgess M; Aarons L
Br J Clin Pharmacol; 2003 Jul; 56(1):46-56. PubMed ID: 12848775
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers.
Nardi-Hiebl S; Ndieyira JW; Al Enzi Y; Al Akkad W; Koch T; Geldner G; Reyher C; Eberhart LHJ
Pain Res Manag; 2021; 2021():2887773. PubMed ID: 34880961
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
[TBL] [Abstract][Full Text] [Related]
20. Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
ten Tije AJ; Synold TW; Spicer D; Verweij J; Doroshow JH; Sparreboom A
Invest New Drugs; 2003 Aug; 21(3):291-8. PubMed ID: 14578679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
